Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Millennium Pharmaceuticals discloses updated results from ongoing phase I trial of MLN-9708

Oct. 7, 2011

Study further elucidates activity of Adva-27a

Oct. 6, 2011

FDA accepts ridaforolimus NDA for filing

Oct. 6, 2011

Dosing begins in phase II PEG-rHuPH20 study

Oct. 6, 2011

Celgene and Agios Pharmaceuticals expand cancer metabolism partnership

Oct. 6, 2011

NDA for mechlorethamine gel accepted for review by FDA

Oct. 6, 2011

Johnson & Johnson discloses first-in-human data on pan-histone deacetylase inhibitor

Oct. 6, 2011

Gliknik receives SBIR contract to advance stradobodies

Oct. 5, 2011

EntreMed reports encouraging phase II results on ENMD-2076

Oct. 5, 2011

Novel PP1 inhibitors synthesized

Oct. 5, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...